The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
India delivered the exceptional performance at the Asian Boxing U15 Championships 2026 and finished with…
As President of United States Donald Trump paid visit to China few days ago, both…
Indian Institute of Tropical Meteorology (IITM) Pune has launched a dedicated startup incubation centre which…
Centre has launched the ₹189.79 crore Mizoram Ginger Mission. This initiative aims to transform the…
The state of Rajasthan entered into the India's fastest growing semiconductor and electronics manufacturing sector…
National Highways Authority of India (NHAI) has launched 'Project Saksham' and to encourage the inclusive…